

October 12, 2021  
SymBio Pharmaceuticals Limited  
Fuminori Yoshida  
Representative Director  
President and Chief Executive Officer  
(Securities Code: 4582)

**SymBio announces commencement of operations of  
SymBio Pharma USA, Inc.**

TOKYO, Japan, October 12, 2021 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, "SymBio" or the "Company") today announced the appointment of Dr. Carolyn Yanavich as the Vice President, and Head of Project Management and Clinical Operations of SymBio Pharma USA, Inc. (SymBio Pharma USA), the Company's wholly-owned U.S. subsidiary established in May 2016. With this appointment, SymBio Pharma USA will begin operations in the U.S. to accelerate the development and commercialization of brincidofovir in the U.S. and Europe as part of the Company's transformation into a global specialty pharmaceutical company. Dr. Carolyn Yanavich will lead the promotion of global clinical trials for an intravenous formulation of brincidofovir (BCV IV) and the organization of SymBio Pharma USA.

Statement from Dr. Carolyn Yanavich: "I am thrilled to join SymBio Pharma USA as we enter this exciting next phase of expansion and increased global capabilities for the Company. SymBio is a patient-centric organization committed to bringing novel therapeutics to the market for underserved therapeutic areas and I look forward to working closely with the leadership team to achieve this goal with brincidofovir. I am confident that brincidofovir has transformative potential as a treatment for a wide host of diseases caused by DNA viruses."

Statement from Mr. Fuminori Yoshida, President and Chief Executive Officer of SymBio: "We are very pleased to welcome Dr. Yanavich, with her outstanding knowledge and experience in the research and development of antiviral infections and anticancer agents, our strategic therapeutic areas, to the management team of SymBio. SymBio Pharma USA will further accelerate the global development of BCV IV to realize SymBio's transformation into a global specialty pharmaceutical company."

**SymBio Pharma USA, Inc. (summary)**

Name	SymBio Pharma USA, Inc.
Address	Durham, North Carolina, USA
President	Fuminori Yoshida
Establishment Date	May 10, 2016
Shareholders	A 100% subsidiary of SymBio Pharmaceuticals Limited
Business Activities	Research and development of pharmaceutical products

**[Contact]**

Investor Relations

Tel: +81 (0)3 5472 1125

**About anti-viral drug Brincidofovir**

SyB V-1901 (Generic Name: Brincidofovir, BCV) is a lipid conjugate of cidofovir (CDV). CDV is an antiviral drug already approved and marketed in the United States and the European Union, but unapproved in Japan. As BCV exhibits not only higher anti-viral activity, but also a superior safety profile in comparison with CDV, BCV is expected to be an effective treatment against a wide spectrum of infectious diseases caused by DNA viruses, including herpes viruses (including CMV), adenovirus, BK virus, papilloma virus, and smallpox virus. Moreover, BCV is an easy-to-use and novel highly active antimultiviral agent with reduced risk of nephrotoxicity, which is a serious side effect of CDV.

Symbio entered into an exclusive global license agreement with Chimerix Inc. (Headquarters: Durham, NC, "Chimerix") for brincidofovir (BCV) on September 30, 2019. Under the terms of the agreement, Chimerix grants Symbio exclusive worldwide rights to develop, manufacture, and commercialize BCV in all human indications, excluding the prevention and treatment of orthopoxvirus infections (which includes smallpox and monkeypox). Chimerix received FDA approval for BCV as a medical countermeasure for smallpox on June 7, 2021.

**About Chimerix**

Chimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious diseases. In June 2021, the U. S. Food and Drug Administration granted approval of TEMBEXA® for the treatment of smallpox as a medical countermeasure. Chimerix has two other advanced clinical-stage development programs, ONC201 and dociparstat sodium (DSTAT). ONC201 is currently in a registrational clinical program for recurrent H3 K27M-mutant glioma and blinded independent central review is expected later in 2021. DSTAT is in development as a potential first-line therapy in acute myeloid leukemia. For further information, please visit the Chimerix website, [www.chimerix.com](http://www.chimerix.com).

**About Symbio Pharmaceuticals Limited**

Symbio Pharmaceuticals Limited was established in March, 2005 by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. In May 2016, the Company incorporated its wholly-owned subsidiary in the U.S., called Symbio Pharma USA, Inc. (Headquarters: Menlo Park, California, President: Mr. Fuminori Yoshida). The Company's underlying corporate mission is to "deliver hope to patients in need" as it aspires to be a leading global specialty biopharmaceutical company dedicated to addressing underserved medical needs.